NCT01981720View on ClinicalTrials.gov

Extension Study of PRX-102 for up to 60 Months

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 16, 2014

Primary Completion Date

August 26, 2020

Study Completion Date

November 9, 2021

Conditions
Fabry Disease
Interventions
BIOLOGICAL

PRX-102 (pegunigalsidase alfa)

PRX-102 1 mg/kg every 2 weeks

Trial Locations (8)

21205

Johns Hopkins University School of Medicine, Baltimore

22030

O & O Alpan, Fairfax

32611

University of Florida, Gainesville

50012

Hospital de Dia Quiron Zaragoza, Zaragoza

52242

University of Iowa Hospitals and Clinics, Iowa City

75226

Institute of Metabolic Disease, Dallas

Unknown

Instituto Privado de Hematologia E Investigacion Clinica (I.P.H.I.C), Asunción

NW3 2QG

The Royal Free Hospital, London

All Listed Sponsors
collaborator

Chiesi Farmaceutici S.p.A.

INDUSTRY

lead

Protalix

INDUSTRY

NCT01981720 - Extension Study of PRX-102 for up to 60 Months | Biotech Hunter | Biotech Hunter